Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975850 | 0.80 | CCR1 (0.53) | CCR1MEN1KMT2AALDH1A1 | |
| SCHEMBL3336371 | 0.79 | MEN1 (0.36) | RIPK1MEN1LMNAKMT2APFKFB3 | |
| SCHEMBL3336374 | 0.79 | MEN1 (0.36) | RIPK1MEN1LMNAKMT2APFKFB3 | |
| SCHEMBL3332400 | 0.77 | CCR1 (0.43) | CCR1RIPK1EGLN1LMNAGRM2 | |
| SCHEMBL20660923 | 0.76 | BACE1 (0.38) | FGFR4RIPK1EGLN1GRM2BACE1 | |
| SCHEMBL20838469 | 0.74 | PTPN5 (0.46) | CCR1FGFR4MAPKAPK2MEN1KMT2A | |
| SCHEMBL5090095 | 0.72 | BACE1 (0.57) | CCR1FGFR4MAPKAPK2ALDH1A1BACE1 | |
| SCHEMBL153259 | 0.71 | BACE1 (0.42) | LMNAALDH1A1BACE1 | |
| SCHEMBL15285083 | 0.70 | PFKFB3 (0.55) | CCR1FGFR4MAPKAPK2MEN1LMNA | |
| SCHEMBL3230593 | 0.70 | CCR1 (0.41) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| CN-101679422-A | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2139888-A2 | IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121687-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | CCR1 2012/4885FGFR4 182/4885MAPKAPK2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.